Maurizio Taramasso1, MD; Paul Sorajja2, MD; Gry Dahle3, MD; Nicolas Dumonteil4, MD; Ulrich Schäfer5, MD; Thomas Modine6, MD; Pavel Overtchouk6, MD; Augustin Coisne6, MD; Georg Nickenig7, MD; Vasilis Babaliaros8, MD; Ahmed A. Khattab1,9,10, MD; Sebastian Ludwig5, MD; Lenard Conradi5, MD
1. University Hospital of Zurich, University of Zurich, Zurich, Switzerland; 2. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN, USA; 3. Department of Cardiothoracic Surgery, Oslo University, Oslo, Norway; 4. Clinique Pasteur, Toulouse, France; 5. University Heart Center, Hamburg, Germany; 6. Cardiovascular Surgery Department, Cœur Poumon CHU de Lille, Lille, France; 7. Heart Center Bonn, University Hospital, Bonn, Germany; 8. Emory Structural Heart and Valve Center, Atlanta, GA, USA; 9. Cardiance Clinic, Pfäffikon, Switzerland; 10. University of Bern, Bern, Switzerland
Transcatheter mitral valve implantation (TMVI) has recently emerged as a treatment option for selected high-risk patients with symptomatic mitral regurgitation (MR).
Although the feasibility of TMVI in patients with previous aortic valve (AV) prostheses has been reported1, the interaction between a TMVI and an AV prosthesis has not previously been well characterised. In particular, the risk of left ventricular outflow tract (LVOT) obstruction after TMVI may be higher in patients with a pre-existing aortic valve prosthesis, due to the presence of concomitant LV hypertrophy. Moreover, the frame of the aortic prosthesis can extend into the LVOT, and ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Interventions for valvular diseaseInterventions for heart failureMitral valve replacement and repairChronic heart failure
Read next article
Outcomes of directional atherectomy for common femoral artery disease